Considering the reports indicating the accelerated clearance of pGSN when complexed with extracellular actin, which is recognized as a crucial mechanism resulting in rapid decrease of pGSN level in patients with sepsis and systemic inflammation [20], we decided to use a dose of gelsolin slightly exceeding the physiological concentration (~400 μg/mL or 40 mg/kg) observed in human blood, to maintain the appropriate concentration of recombinant protein throughout the duration of treatment, i.e., 24 h. The gene discussed is GSN; the disease is Sepsis.